Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;16(4):391-397.
doi: 10.1007/s11901-017-0378-2. Epub 2017 Nov 13.

Natural History of NAFLD/NASH

Mattias Ekstedt  1 , Patrik Nasr  1 , Stergios Kechagias  1
Affiliations
Review

Natural History of NAFLD/NASH

Mattias Ekstedt et al. Curr Hepatol Rep. 2017.

Abstract

Purpose of review: The purpose of this review is to summarize the latest knowledge on the natural history of non-alcoholic fatty liver disease (NAFLD). The review focuses on mortality, liver-related complications, and histological course.

Recent findings: Studies during the last decade have established NAFLD as a potentially progressive liver disease. Age and diabetes are the strongest clinical predictors of progressive disease. Fibrosis stage is the most important histological variable to predict mortality and liver-related complications. So far, no study has been able to show that non-alcoholic steatohepatitis at baseline predicts mortality or future liver-related complications when adjusting for fibrosis.

Summary: The outlines of the natural history of NAFLD have become clearer during the last decade. There is limited data on factors that predict clinical progression. Prospective longitudinal studies are needed to help us predict worse outcome in individual patients.

Keywords: Liver histology; Mortality; Natural history; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsMattias Ekstedt, Patrik Nasr, and Stergios Kechagias each declare no potential conflicts of interest.This article does not contain any studies with human or animal subjects performed by any of the authors.

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431. - DOI - PubMed
    1. Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17(6):510–519. doi: 10.1111/obr.12407. - DOI - PubMed
    1. Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111(8):1133–1140. doi: 10.1038/ajg.2016.178. - DOI - PubMed
    1. Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56(5):1145–1151. doi: 10.1016/j.jhep.2011.12.011. - DOI - PubMed
    1. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–131. doi: 10.1053/j.gastro.2010.09.038. - DOI - PubMed